



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

February 10, 2021

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code: 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub: Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on December 31, 2020.**

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular nos. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find

1. Standalone unaudited financial results for the quarter ended on December 31, 2020 accompanied by limited review report; and
2. Consolidated unaudited financial results for the quarter ended on December 31, 2020 accompanied by limited review report.

These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 4.40 p.m. and concluded at 6.20 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

**For J. B. Chemicals & Pharmaceuticals Limited**

**M. C. Mehta**

**Company Secretary and Vice President - Compliance**

Encl: As above



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2020

Sr. No.	Particulars	(₹ in lakhs)					
		Quarter ended			Nine months ended		Year ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	50,034.14	41,177.85	38,495.45	1,40,174.42	1,22,387.92	1,64,074.44
2	Other income (Refer Note 4)	5,586.24	818.78	1,602.19	8,658.56	4,646.64	4,934.27
3	<b>Total income (1+2)</b>	<b>55,620.38</b>	<b>41,996.63</b>	<b>40,097.64</b>	<b>1,48,832.98</b>	<b>1,27,034.56</b>	<b>1,69,008.71</b>
4	<b>Expenses</b>						
a.	Cost of materials consumed	12,856.23	15,204.58	9,926.20	40,718.64	33,163.93	45,210.43
b.	Purchases of stock-in-trade	1,932.62	1,302.57	2,818.88	7,527.73	8,682.24	11,450.09
c.	Changes in inventories of finished goods, work-in- progress and stock-in-trade	1,782.63	(4,387.47)	116.46	(3,046.49)	1,299.85	252.83
d.	Employee benefits expense	7,496.65	7,302.88	7,355.40	22,953.68	21,388.56	29,378.09
e.	Finance costs	108.18	169.59	85.28	650.89	253.08	293.51
f.	Depreciation and amortization expense	1,705.54	1,714.01	1,654.59	5,116.28	4,839.82	6,509.05
g.	Other expenses	9,305.78	11,181.64	9,870.20	28,971.46	30,142.94	40,958.54
	<b>Total expenses (4)</b>	<b>35,187.63</b>	<b>32,487.80</b>	<b>31,827.01</b>	<b>1,02,892.19</b>	<b>99,770.42</b>	<b>1,34,052.54</b>
5	<b>Profit before exceptional item and tax (3-4)</b>	<b>20,432.75</b>	<b>9,508.83</b>	<b>8,270.63</b>	<b>45,940.79</b>	<b>27,264.14</b>	<b>34,956.17</b>
6	<b>Exceptional item (Refer Note 5)</b>	-	-	-	-	-	<b>1,000.00</b>
7	<b>Profit before tax (5-6)</b>	<b>20,432.75</b>	<b>9,508.83</b>	<b>8,270.63</b>	<b>45,940.79</b>	<b>27,264.14</b>	<b>33,956.17</b>
8	<b>Tax expense</b>						
a.	Current tax	4,800.00	2,355.00	1,851.22	10,900.00	6,151.99	8,201.99
b.	Deferred tax	465.96	55.52	202.15	583.16	(615.68)	(1,060.22)
	<b>Total tax expense</b>	<b>5,265.96</b>	<b>2,410.52</b>	<b>2,053.37</b>	<b>11,483.16</b>	<b>5,536.31</b>	<b>7,141.77</b>
9	<b>Net profit after tax for the period (7-8)</b>	<b>15,166.79</b>	<b>7,098.31</b>	<b>6,217.26</b>	<b>34,457.63</b>	<b>21,727.83</b>	<b>26,814.40</b>
10	<b>Other comprehensive income</b>						
a.	Items that will not be reclassified to profit or loss	(724.63)	(461.44)	(10.20)	(1,336.07)	(354.97)	(676.74)
b.	Income tax relating to items that will not be reclassified to profit or loss	182.37	116.14	2.57	336.26	89.34	170.32
	<b>Other comprehensive income (net of tax)</b>	<b>(542.26)</b>	<b>(345.30)</b>	<b>(7.63)</b>	<b>(999.81)</b>	<b>(265.63)</b>	<b>(506.42)</b>
11	<b>Total comprehensive income after tax (9+10)</b>	<b>14,624.53</b>	<b>6,753.01</b>	<b>6,209.63</b>	<b>33,457.82</b>	<b>21,462.20</b>	<b>26,307.98</b>
12	Paid up equity share capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,604.73	1,545.64	1,604.73	1,545.64
13	Other equity						1,42,983.44
14	<b>Earnings per share (not annualised for the quarter and nine months)</b>						
(1)	Basic in ₹	19.63	9.18	7.75	44.59	27.08	33.70
(2)	Diluted in ₹	19.63	9.18	7.75	44.59	27.08	33.70

### Notes:

- The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 10, 2021. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
- The statutory auditors have carried out limited review of the results for the quarter and nine months ended December 31, 2020.
- This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- Other income for the quarter and nine months ended December 31, 2020 include Rs. 3,368.66 lakhs being consideration towards sale of one of the Company's product registration along with its marketing authorization and trademark.
- Exceptional item for the year ended March 31, 2020 represents charge of one-time compensation ordered by the Supreme Court vide judgement dated April 01, 2020 in respect of the appeal filed by the Company against Order dated January 08, 2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle, which has been paid by the Company.

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

- 6 With announcements of phased lifting of the lockdown by the Government in the country, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine on mass scale may take time and hence, the Company continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its standalone financial statements. The Company has also considered impact of Covid-19 pandemic on future operations and financial projections. Based on the above assessment, the Company is of the view that the carrying amounts of the assets will be realised. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
- 7 The President has given his assent to the Code on Social Security, 2020 ("Code") in September 2020. On November 13, 2020 the Ministry of Labour and Employment has released draft rules for the Code. The Company will assess the impact once the subject rules are notified and will give appropriate impact to its financial statements in the period in which the Code becomes effective.
- 8 The Company has only one reportable business segment viz. "Pharmaceuticals".
- 9 The Board of Directors, at its meeting held today, have declared an interim dividend of ₹ 8.50 per equity share of ₹ 2 each for the year 2020-21. The record date fixed for the purpose of ascertaining the entitlement is February 22, 2021.

Date : 10/02/2021  
Place : Mumbai

EH RKB

For J. B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra  
Chief Executive Officer and Whole-time Director

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Company"), for the quarter and nine months ended December 31, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*EH RKH*

**Deloitte  
Haskins & Sells LLP**

5. The comparative financial information of the Company for the quarter ended September 30, 2020, for the quarter and nine months ended December 31, 2019 and for the year ended March 31, 2020 prepared in accordance with Ind AS, included in this Statement, have been reviewed / audited by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information dated November 10, 2020, February 4, 2020 and June 25, 2020 respectively, expressed an unmodified conclusion / opinion, as applicable.

Our conclusion on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
(Partner)  
(Membership No. 36920)  
(UDIN: 21036920AAAAAL7127)

EH

Place: Mumbai  
Date: February 10, 2021





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2020

(₹ in lakhs)

Sr. No	Particulars	Quarter ended			Nine months ended		Year ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	50,034.14	41,177.85	38,495.45	1,40,174.42	1,22,387.92	1,64,074.44
2	Other income (Refer Note 4)	5,586.24	818.78	1,602.19	8,658.56	4,646.64	4,934.27
3	<b>Total income (1+2)</b>	<b>55,620.38</b>	<b>41,996.63</b>	<b>40,097.64</b>	<b>1,48,832.98</b>	<b>1,27,034.56</b>	<b>1,69,008.71</b>
4	<b>Expenses</b>						
a.	Cost of materials consumed	12,856.23	15,204.58	9,926.20	40,718.64	33,163.93	45,210.43
b.	Purchases of stock-in-trade	1,932.62	1,302.57	2,818.88	7,527.73	8,682.24	11,450.09
c.	Changes in inventories of finished goods, work-in- progress and stock-in-trade	1,782.63	(4,387.47)	116.46	(3,046.49)	1,299.85	252.83
d.	Employee benefits expense	7,496.65	7,302.88	7,355.40	22,953.68	21,388.56	29,378.09
e.	Finance costs	108.18	169.59	85.28	650.89	253.08	293.51
f.	Depreciation and amortization expense	1,705.54	1,714.01	1,654.59	5,116.28	4,839.82	6,509.05
g.	Other expenses	9,305.78	11,181.64	9,870.20	28,971.46	30,142.94	40,958.54
	<b>Total expenses (4)</b>	<b>35,187.63</b>	<b>32,487.80</b>	<b>31,827.01</b>	<b>1,02,892.19</b>	<b>99,770.42</b>	<b>1,34,052.54</b>
5	<b>Profit before exceptional item and tax (3-4)</b>	<b>20,432.75</b>	<b>9,508.83</b>	<b>8,270.63</b>	<b>45,940.79</b>	<b>27,264.14</b>	<b>34,956.17</b>
6	<b>Exceptional item (Refer Note 5)</b>	-	-	-	-	-	<b>1,000.00</b>
7	<b>Profit before tax (5-6)</b>	<b>20,432.75</b>	<b>9,508.83</b>	<b>8,270.63</b>	<b>45,940.79</b>	<b>27,264.14</b>	<b>33,956.17</b>
8	<b>Tax expense</b>						
a.	Current tax	4,800.00	2,355.00	1,851.22	10,900.00	6,151.99	8,201.99
b.	Deferred tax	465.96	55.52	202.15	583.16	(615.68)	(1,060.22)
	<b>Total tax expense</b>	<b>5,265.96</b>	<b>2,410.52</b>	<b>2,053.37</b>	<b>11,483.16</b>	<b>5,536.31</b>	<b>7,141.77</b>
9	<b>Net profit after tax for the period (7-8)</b>	<b>15,166.79</b>	<b>7,098.31</b>	<b>6,217.26</b>	<b>34,457.63</b>	<b>21,727.83</b>	<b>26,814.40</b>
10	<b>Other comprehensive income</b>						
a.	Items that will not be reclassified to profit or loss	(724.63)	(461.44)	(10.20)	(1,336.07)	(354.97)	(676.74)
b.	Income tax relating to items that will not be reclassified to profit or loss	182.37	116.14	2.57	336.26	89.34	170.32
	<b>Other comprehensive income (net of tax)</b>	<b>(542.26)</b>	<b>(345.30)</b>	<b>(7.63)</b>	<b>(999.81)</b>	<b>(265.63)</b>	<b>(506.42)</b>
11	<b>Total comprehensive income after tax (9+10)</b>	<b>14,624.53</b>	<b>6,753.01</b>	<b>6,209.63</b>	<b>33,457.82</b>	<b>21,462.20</b>	<b>26,307.98</b>
12	Paid up equity share capital (Face value of ₹ 2 each)	1,545.64	1,545.64	1,604.73	1,545.64	1,604.73	1,545.64
13	Other equity						1,42,983.44
14	<b>Earnings per share (not annualised for the quarter and nine months)</b>						
(1)	Basic in ₹	19.63	9.18	7.75	44.59	27.08	33.70
(2)	Diluted in ₹	19.63	9.18	7.75	44.59	27.08	33.70

### Notes:

- The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 10, 2021. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
- The statutory auditors have carried out limited review of the results for the quarter and nine months ended December 31, 2020.
- This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- Other income for the quarter and nine months ended December 31, 2020 include Rs. 3,368.66 lakhs being consideration towards sale of one of the Company's product registration along with its marketing authorization and trademark.
- Exceptional item for the year ended March 31, 2020 represents charge of one-time compensation ordered by the Supreme Court vide judgement dated April 01, 2020 in respect of the appeal filed by the Company against Order dated January 08, 2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle, which has been paid by the Company.

### Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

### Corporate Office:

Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

☎ +91 22 2439 5200 / 2439 5500

☎ +91 22 2431 5331 / 2431 5334

@ info@jbcpl.com

🌐 www.jbcpl.com

CIN: L24390MH1976PLC019380



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

- 6 With announcements of phased lifting of the lockdown by the Government in the country, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine on mass scale may take time and hence, the Company continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its standalone financial statements. The Company has also considered impact of Covid-19 pandemic on future operations and financial projections. Based on the above assessment, the Company is of the view that the carrying amounts of the assets will be realised. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Company.
- 7 The President has given his assent to the Code on Social Security, 2020 ("Code") in September 2020. On November 13, 2020 the Ministry of Labour and Employment has released draft rules for the Code. The Company will assess the impact once the subject rules are notified and will give appropriate impact to its financial statements in the period in which the Code becomes effective.
- 8 The Company has only one reportable business segment viz. "Pharmaceuticals".
- 9 The Board of Directors, at its meeting held today, have declared an interim dividend of ₹ 8.50 per equity share of ₹ 2 each for the year 2020-21. The record date fixed for the purpose of ascertaining the entitlement is February 22, 2021.

For J. B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra

Chief Executive Officer and Whole-time Director

Date : 10/02/2021

Place : Mumbai

EH RCB

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Energy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2020

(₹ in lakhs)

Sr.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	54,821.69	44,356.43	42,863.25	1,51,406.62	1,33,115.98	1,77,472.91
2	Other income (Refer Note 5)	5,595.25	839.27	1,637.96	8,703.48	4,749.61	5,066.99
3	<b>Total income (1+2)</b>	<b>60,416.94</b>	<b>45,195.70</b>	<b>44,501.21</b>	<b>1,60,110.10</b>	<b>1,37,865.59</b>	<b>1,82,539.90</b>
4	<b>Expenses</b>						
a.	Cost of materials consumed	12,853.76	15,207.85	9,970.78	40,722.15	33,171.47	45,248.04
b.	Purchases of stock-in-trade	5,959.61	3,554.20	5,403.09	16,024.05	14,690.65	18,230.77
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(124.28)	(5,379.17)	(339.09)	(6,048.66)	518.08	(399.27)
d.	Employee benefits expense	8,469.83	8,107.14	8,231.58	25,443.57	23,739.16	32,291.67
e.	Finance costs	109.10	171.57	85.32	655.19	253.08	302.96
f.	Depreciation and amortization expense	1,739.28	1,744.64	1,674.86	5,213.31	4,893.30	6,632.23
g.	Other expenses	10,563.45	11,856.50	10,637.27	31,614.16	32,412.97	44,344.27
	<b>Total expenses (4)</b>	<b>39,570.75</b>	<b>35,262.73</b>	<b>35,663.81</b>	<b>1,13,623.77</b>	<b>1,09,678.71</b>	<b>1,46,650.67</b>
5	<b>Profit before exceptional item and tax (3-4)</b>	<b>20,846.19</b>	<b>9,932.97</b>	<b>8,837.40</b>	<b>46,486.33</b>	<b>28,186.88</b>	<b>35,889.23</b>
6	<b>Exceptional item (Refer Note 6)</b>	-	-	-	-	-	<b>1,000.00</b>
7	<b>Profit before tax (5-6)</b>	<b>20,846.19</b>	<b>9,932.97</b>	<b>8,837.40</b>	<b>46,486.33</b>	<b>28,186.88</b>	<b>34,889.23</b>
8	<b>Tax expense</b>						
a.	Current tax	4,968.24	2,447.32	2,011.03	11,222.56	6,529.42	8,439.38
b.	Deferred tax	449.55	93.30	181.69	492.48	(574.66)	(789.36)
	<b>Total tax expense</b>	<b>5,417.79</b>	<b>2,540.62</b>	<b>2,192.72</b>	<b>11,715.04</b>	<b>5,954.76</b>	<b>7,650.02</b>
9	<b>Net profit after tax for the period (7-8)</b>	<b>15,428.40</b>	<b>7,392.35</b>	<b>6,644.68</b>	<b>34,771.29</b>	<b>22,232.12</b>	<b>27,239.21</b>
10	<b>Other comprehensive income</b>						
a.	Items that will not be reclassified to profit or loss	(724.63)	(461.44)	(10.20)	(1,336.07)	(354.97)	(676.74)
b.	Income tax relating to items that will not be reclassified to profit or loss	182.37	116.14	2.57	336.26	89.34	170.32
c.	Items that will be reclassified to profit or loss	1,402.66	(215.57)	704.08	1,603.12	581.45	(991.19)
d.	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other comprehensive income (net of tax)</b>	<b>860.40</b>	<b>(560.87)</b>	<b>696.45</b>	<b>603.31</b>	<b>315.82</b>	<b>(1,497.61)</b>
11	<b>Total comprehensive income after tax (9+10)</b>	<b>16,288.80</b>	<b>6,831.48</b>	<b>7,341.13</b>	<b>35,374.60</b>	<b>22,547.94</b>	<b>25,741.60</b>
12	<b>Net profit after tax for the period attributable to:</b>						
-	owners of the company	15,410.66	7,382.28	6,627.72	34,735.10	22,190.78	27,204.71
-	non controlling interest	17.74	10.07	16.96	36.19	41.34	34.50
13	<b>Other comprehensive income for the period attributable to:</b>						
-	owners of the company	810.80	(569.89)	671.00	535.27	305.01	(1,432.88)
-	non controlling interest	49.60	9.02	25.45	68.04	10.81	(64.73)
14	<b>Total comprehensive income after tax attributable to:</b>						
-	owners of the company	16,221.46	6,812.39	7,298.72	35,270.37	22,495.79	25,771.83
-	non controlling interest	67.34	19.09	42.41	104.23	52.15	(30.23)
15	<b>Paid up equity share capital (Face value of ₹ 2 each)</b>	<b>1,545.64</b>	<b>1,545.64</b>	<b>1,604.73</b>	<b>1,545.64</b>	<b>1,604.73</b>	<b>1,545.64</b>
16	<b>Other equity</b>						<b>1,42,003.29</b>
17	<b>Earnings per share (not annualised for the quarter and nine months)</b>						
(1)	Basic in ₹	19.94	9.55	8.26	44.95	27.66	34.20
(2)	Diluted in ₹	19.94	9.55	8.26	44.95	27.66	34.20

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## Notes:

- 1 The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 10, 2021. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
- 2 The statutory auditors have carried out limited review of the results for the quarter and nine months ended December 31, 2020.
- 3 This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- 4 The unaudited consolidated financial results of the Company, its two wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
- 5 Other income for the quarter and nine months ended December 31, 2020 include Rs. 3,368.66 lakhs being consideration towards sale of one of the Holding Company's product registration along with its marketing authorization and trademark.
- 6 Exceptional item for the year ended March 31, 2020 represents charge of one-time compensation ordered by the Supreme Court vide judgement dated April 01, 2020 in respect of the appeal filed by the Holding Company against Order dated January 08, 2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle, which has been paid by the Holding Company.
- 7 With announcements of phased lifting of the lockdown in India and globally, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine on mass scale may take time and hence, the Group continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its consolidated financial statements. The Group has also considered impact of Covid-19 pandemic on future operations and financial projections. Based on the above assessment, the Group is of the view that the carrying amounts of the assets will be realised. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Group.
- 8 The President has given his assent to the Code on Social Security, 2020 ("Code") in September 2020. On November 13, 2020 the Ministry of Labour and Employment has released draft rules for the Code. The Group will assess the impact once the subject rules are notified and will give appropriate impact to its financial statements in the period in which the Code becomes effective.
- 9 The Group has only one reportable business segment viz. "Pharmaceuticals".
- 10 The Board of Directors of Holding Company, at its meeting held today, have declared an interim dividend of ₹ 8.50 per equity share of ₹ 2 each for the year 2020-21. The record date fixed for the purpose of ascertaining the entitlement is February 22, 2021.

For J. B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra

Chief Executive Officer and Whole-time Director

Date : 10/02/2021

Place : Mumbai

EM RCB

## Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

## Corporate Office:

Energy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
CONSOLIDATED FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF  
J. B. CHEMICALS & PHARMACEUTICALS LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **J. B. CHEMICALS & PHARMACEUTICALS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2020 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent – J. B. Chemicals & Pharmaceuticals Limited

Direct Subsidiaries – OOO Unique Pharmaceutical Laboratories; and  
Unique Pharmaceutical Laboratories FZE.

Step down Subsidiary - Biotech Laboratories (Pty.) Ltd.

EH PKU

Page 1 of 3



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflect total revenues of Rs. 6,028.19 Lakhs and Rs. 15,760.55 Lakhs for the quarter and nine months ended December 31, 2020 respectively, total net profit after tax of Rs. 375.83 Lakhs and Rs. 763.39 Lakhs for the quarter and nine months ended December 31, 2020 respectively and total comprehensive income of Rs. 375.83 Lakhs and Rs. 763.39 Lakhs for the quarter and nine months ended December 31, 2020 respectively, as considered in the Statement. This interim financial information has been reviewed by other auditor whose report has been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. The consolidated unaudited financial results include the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of Rs. 2,333.19 Lakhs and Rs. 4,964.98 Lakhs for the quarter and nine months ended December 31, 2020 respectively, total profit after tax of Rs. 115.81 Lakhs and Rs. 97.86 Lakhs for the quarter and nine months ended December 31, 2020 respectively and total comprehensive income of Rs. 115.81 Lakhs and Rs. 97.86 Lakhs for the quarter and nine months ended December 31, 2020 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

EH RKH

**Deloitte  
Haskins & Sells LLP**

8. The comparative consolidated financial information of the Group for the quarter ended September 30, 2020, for the quarter and nine months ended December 31, 2019 and for the year ended March 31, 2020 prepared in accordance with Ind AS, included in this Statement, have been reviewed / audited by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information dated November 10, 2020, February 4, 2020 and June 25, 2020 respectively, expressed an unmodified conclusion / opinion, as applicable.

Our conclusion on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



Rajesh K. Hiranandani  
(Partner)  
(Membership No. 36920)  
(UDIN: 21036920AAAAAM9283)

EH

Place: Mumbai  
Date: February 10, 2021





# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2020

(₹ in lakhs)

Sr.No.	Particulars	Quarter ended			Nine months ended		Year ended
		31-12-2020	30-09-2020	31-12-2019	31-12-2020	31-12-2019	31-03-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	54,821.69	44,356.43	42,863.25	1,51,406.62	1,33,115.98	1,77,472.91
2	Other income (Refer Note 5)	5,595.25	839.27	1,637.96	8,703.48	4,749.61	5,066.99
3	<b>Total income (1+2)</b>	<b>60,416.94</b>	<b>45,195.70</b>	<b>44,501.21</b>	<b>1,60,110.10</b>	<b>1,37,865.59</b>	<b>1,82,539.90</b>
4	<b>Expenses</b>						
a.	Cost of materials consumed	12,853.76	15,207.85	9,970.78	40,722.15	33,171.47	45,248.04
b.	Purchases of stock-in-trade	5,959.61	3,554.20	5,403.09	16,024.05	14,690.65	18,230.77
c.	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(124.28)	(5,379.17)	(339.09)	(6,048.66)	518.08	(399.27)
d.	Employee benefits expense	8,469.83	8,107.14	8,231.58	25,443.57	23,739.16	32,291.67
e.	Finance costs	109.10	171.57	85.32	655.19	253.08	302.96
f.	Depreciation and amortization expense	1,739.28	1,744.64	1,674.86	5,213.31	4,893.30	6,632.23
g.	Other expenses	10,563.45	11,856.50	10,637.27	31,614.16	32,412.97	44,344.27
	<b>Total expenses (4)</b>	<b>39,570.75</b>	<b>35,262.73</b>	<b>35,663.81</b>	<b>1,13,623.77</b>	<b>1,09,678.71</b>	<b>1,46,650.67</b>
5	<b>Profit before exceptional item and tax (3-4)</b>	<b>20,846.19</b>	<b>9,932.97</b>	<b>8,837.40</b>	<b>46,486.33</b>	<b>28,186.88</b>	<b>35,889.23</b>
6	<b>Exceptional item (Refer Note 6)</b>	-	-	-	-	-	<b>1,000.00</b>
7	<b>Profit before tax (5-6)</b>	<b>20,846.19</b>	<b>9,932.97</b>	<b>8,837.40</b>	<b>46,486.33</b>	<b>28,186.88</b>	<b>34,889.23</b>
8	<b>Tax expense</b>						
a.	Current tax	4,968.24	2,447.32	2,011.03	11,222.56	6,529.42	8,439.38
b.	Deferred tax	449.55	93.30	181.69	492.48	(574.66)	(789.36)
	<b>Total tax expense</b>	<b>5,417.79</b>	<b>2,540.62</b>	<b>2,192.72</b>	<b>11,715.04</b>	<b>5,954.76</b>	<b>7,650.02</b>
9	<b>Net profit after tax for the period (7-8)</b>	<b>15,428.40</b>	<b>7,392.35</b>	<b>6,644.68</b>	<b>34,771.29</b>	<b>22,232.12</b>	<b>27,239.21</b>
10	<b>Other comprehensive income</b>						
a.	Items that will not be reclassified to profit or loss	(724.63)	(461.44)	(10.20)	(1,336.07)	(354.97)	(676.74)
b.	Income tax relating to items that will not be reclassified to profit or loss	182.37	116.14	2.57	336.26	89.34	170.32
c.	Items that will be reclassified to profit or loss	1,402.66	(215.57)	704.08	1,603.12	581.45	(991.19)
d.	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Other comprehensive income (net of tax)</b>	<b>860.40</b>	<b>(560.87)</b>	<b>696.45</b>	<b>603.31</b>	<b>315.82</b>	<b>(1,497.61)</b>
11	<b>Total comprehensive income after tax (9+10)</b>	<b>16,288.80</b>	<b>6,831.48</b>	<b>7,341.13</b>	<b>35,374.60</b>	<b>22,547.94</b>	<b>25,741.60</b>
12	<b>Net profit after tax for the period attributable to:</b>						
-	owners of the company	15,410.66	7,382.28	6,627.72	34,735.10	22,190.78	27,204.71
-	non controlling interest	17.74	10.07	16.96	36.19	41.34	34.50
13	<b>Other comprehensive income for the period attributable to:</b>						
-	owners of the company	810.80	(569.89)	671.00	535.27	305.01	(1,432.88)
-	non controlling interest	49.60	9.02	25.45	68.04	10.81	(64.73)
14	<b>Total comprehensive income after tax attributable to:</b>						
-	owners of the company	16,221.46	6,812.39	7,298.72	35,270.37	22,495.79	25,771.83
-	non controlling interest	67.34	19.09	42.41	104.23	52.15	(30.23)
15	<b>Paid up equity share capital (Face value of ₹ 2 each)</b>	<b>1,545.64</b>	<b>1,545.64</b>	<b>1,604.73</b>	<b>1,545.64</b>	<b>1,604.73</b>	<b>1,545.64</b>
16	<b>Other equity</b>						<b>1,42,003.29</b>
17	<b>Earnings per share (not annualised for the quarter and nine months)</b>						
(1)	Basic in ₹	19.94	9.55	8.26	44.95	27.66	34.20
(2)	Diluted in ₹	19.94	9.55	8.26	44.95	27.66	34.20

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## Notes:

- 1 The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on February 10, 2021. The results of the Company are available for investors at [www.jbcpl.com](http://www.jbcpl.com), [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com).
- 2 The statutory auditors have carried out limited review of the results for the quarter and nine months ended December 31, 2020.
- 3 This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 (as amended) (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies, to the extent applicable.
- 4 The unaudited consolidated financial results of the Company, its two wholly owned subsidiaries and a step-down subsidiary ("the Group") have been prepared by applying Ind AS 110 on Consolidated Financial Statements.
- 5 Other income for the quarter and nine months ended December 31, 2020 include Rs. 3,368.66 lakhs being consideration towards sale of one of the Holding Company's product registration along with its marketing authorization and trademark.
- 6 Exceptional item for the year ended March 31, 2020 represents charge of one-time compensation ordered by the Supreme Court vide judgement dated April 01, 2020 in respect of the appeal filed by the Holding Company against Order dated January 08, 2016 passed by the National Green Tribunal. The Supreme Court has, inter alia, set aside the closure of Company's Active Pharmaceutical Ingredients Unit at Panoli and ordered deposit of this compensation on the basis of precautionary principle, which has been paid by the Holding Company.
- 7 With announcements of phased lifting of the lockdown in India and globally, people movement and business activities are gradually coming back to normalcy. However, concerns of Covid-19 pandemic still continue as availability of vaccine on mass scale may take time and hence, the Group continues to follow necessary safety guidelines and assess the situation based on internal and external information in making various estimates and assessing recoverability of assets in relation to its consolidated financial statements. The Group has also considered impact of Covid-19 pandemic on future operations and financial projections. Based on the above assessment, the Group is of the view that the carrying amounts of the assets will be realised. The Management will continue to closely monitor the changes to economic conditions in future and its impact on the Group.
- 8 The President has given his assent to the Code on Social Security, 2020 ("Code") in September 2020. On November 13, 2020 the Ministry of Labour and Employment has released draft rules for the Code. The Group will assess the impact once the subject rules are notified and will give appropriate impact to its financial statements in the period in which the Code becomes effective.
- 9 The Group has only one reportable business segment viz. "Pharmaceuticals".
- 10 The Board of Directors of Holding Company, at its meeting held today, have declared an interim dividend of ₹ 8.50 per equity share of ₹ 2 each for the year 2020-21. The record date fixed for the purpose of ascertaining the entitlement is February 22, 2021.

For J. B. Chemicals & Pharmaceuticals Ltd.

Nikhil Chopra  
Chief Executive Officer and Whole-time Director

Date : 10/02/2021  
Place : Mumbai

EH RLB

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380